Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.
The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.
2024 continues to be a big year for US politics. As well as a presidential election, there are several pieces of legislation that either are affecting or will affect our sector. Watch the recording to learn more about all three of these developments, and what it will mean for you as a UK biotech.
The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.
NHS England has published a consultation document which sets out proposals for updating the NHS Commercial Framework for New Medicines. The BIA has responded to the consultation on updating the NHS commercial framework for new medicines.
